Cyclodextrin-based nanosponges: a versatile platform for cancer nanotherapeutics development

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 8, Issue 4, 2016, Pages 579-601

  Swaminathan, Shankar ^a   Cavalli, Roberta ^b   Trotta, Francesco ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; CYCLODEXTRINS; DRUG PRODUCTS; FUNCTIONAL POLYMERS; MEDICAL APPLICATIONS; MOLECULES; POLYMERS;

ANTICANCER MOLECULES; BIOMEDICAL APPLICATIONS; CAMPTOTHECIN (CPT); CANCER THERAPEUTICS; PERMEABILITY ENHANCEMENT; POLYMERIC SYSTEMS; STIMULI-SENSITIVE; SUSTAINED RELEASE;

DISEASES;

CAMPTOTHECIN; CURCUMIN; CYCLODEXTRIN; DOXORUBICIN; FLUOROURACIL; NANOMATERIAL; NANOPARTICLE; NANOSPONGE; PACLITAXEL; QUERCETIN; RESVERATROL; TAMOXIFEN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOMA; CANCER THERAPY; COLON CARCINOMA; DRUG DELIVERY SYSTEM; HEAD AND NECK TUMOR; HUMAN; KAPOSI SARCOMA; LUNG CANCER; LUNG CARCINOMA; LYMPHOMA; MELANOMA; NANOMEDICINE; NANOTECHNOLOGY; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PARTICLE SIZE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SARCOMA; STOMACH CARCINOMA; ZETA POTENTIAL;

EID: 84975048560     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.1384     Document Type: Review

References (157)

1. Feynman R . There's plenty of room at the bottom. Eng Sci 1960, 23:22–36.
2. Venditto VJ, Szoka FC Jr . Cancer nanomedicines: so many papers and so few drugs!. Adv Drug Deliv Rev 2013, 65:80–88.
3. Duncan R, Gaspar R . Nanomedicine(s) under the microscope. Mol Pharm 2011, 8:2101–2141.
4. Juliano R . Nanomedicine: is the wave cresting? Nat Rev Drug Discov 2013, 12:171–172.
5. Gidwani B, Vyas A . A comprehensive review on cyclodextrin-based carriers for delivery of chemotherapeutic cytotoxic anticancer drugs. BioMed Res Int 2015, 2015:15pp. doi: http://dx.doi.org/10.1155/2015/198268.
6. Zhang J, Lan CQ, Post M, Simard B, Deslandes Y, Hsieh TH . Design of nanoparticles as drug carriers for cancer therapy. Cancer Genomics Proteomics 2006, 3:147–157.
7. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC . Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014, 66:2–25.
8. Brigger I, Dubernet C, Couvreur P . Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 2012, 54:631–651.
9. Bonnet V, Gervaise C, Djedaïni-Pilard F, Furlan A, Sarazin C . Cyclodextrin nanoassemblies: a promising tool for drug delivery. Drug Discov Today 2015, 20:1120-1126. doi: 10.1016/j.drudis.2015.05.008.
10. Trotta F, Zanetti M, Cavalli R . Cyclodextrin-based nanosponges as drug carriers. Beilstein J Org Chem 2012, 8:2091–2099.
11. Li D, Ma M . Nanosponges for water purification. Clean Prod Process 2000, 2:112–116.
12. Cavalli R, Trotta F, Tumiatti W . Cyclodextrin-based nanosponges for drug delivery. J Incl Phenom Macrocycl Chem 2006, 56:209–213.
13. Trotta F, Tumiatti W . Cross-linked polymers based on cyclodextrins for removing polluting agents. 2003.
14. Anandam S, Selvamuthukumar S . Fabrication of cyclodextrin nanosponges for quercetin delivery: physicochemical characterization, photostability, and antioxidant effects. J Mater Sci 2014, 49:8140–8153.
15. Ansari KA, Vavia PR, Trotta F, Cavalli R . Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study. AAPS PharmSciTech 2011, 12:279–286.
16. Cavalli R, Akhter AK, Bisazza A, Giustetto P, Trotta F, Vavia P . Nanosponge formulations as oxygen delivery systems. Int J Pharm 2010, 402:254–257.
17. Darandale SS, Vavia PR . Cyclodextrin-based nanosponges of curcumin: formulation and physicochemical characterization. J Incl Phenom Macrocycl Chem 2013, 75:315–322.
18. Jain D, Gursalkar T, Bajaj A . Nanosponges of an anticancer agent for potential treatment of brain tumors. Am J Neuroprot Neuroregen 2013, 5:32–43.
19. Lembo D, Swaminathan S, Donalisio M, Civra A, Pastero L, Aquilano D, Vavia P, Trotta F, Cavalli R . Encapsulation of acyclovir in new carboxylated cyclodextrin-based nanosponges improves the agent's antiviral efficacy. Int J Pharm 2013, 443:262–272.
20. Swaminathan S, Pastero L, Serpe L, Trotta F, Vavia P, Aquilano D, Trotta M, Zara G, Cavalli R . Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity. Eur J Pharm Biopharm 2010, 74:193–201.
21. Swaminathan S, Vavia P, Trotta F, Cavalli R, Tumbiolo S, Bertinetti L, Coluccia S . Structural evidence of differential forms of nanosponges of β-cyclodextrin and its effect on solubilization of a model drug. J Incl Phenom Macrocycl Chem 2013, 76:201–211.
22. Swaminathan S, Vavia PR, Trotta F, Cavalli R . Nanosponges encapsulating dexamethasone for ocular delivery: formulation design, physicochemical characterization, safety and corneal permeability assessment. J Biomed Nanotechnol 2013, 9:998–1007.
23. Swaminathan S, Vavia PR, Trotta F, Torne S . Formulation of β cyclodextrin based nanosponges of itraconazole. J Incl Phenom Macrocycl Chem 2007, 57:89–94.
24. Torne S, Darandale S, Vavia P, Trotta F, Cavalli R . Cyclodextrin-based nanosponges: effective nanocarrier for tamoxifen delivery. Pharm Dev Technol 2013, 18:619–625.
25. Torne SJ, Ansari KA, Vavia PR, Trotta F, Cavalli R . Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Drug Deliv 2010, 17:419–425.
26. Trotta F, Cavalli R, Martina K, Biasizzo M, Vitillo J, Bordiga S, Vavia P, Ansari K . Cyclodextrin nanosponges as effective gas carriers. J Incl Phenom Macrocycl Chem 2011, 71:189–194.
27. Vavia PR, Swaminathan S, Trotta F, Cavalli R . Applications of nanosponges in drug delivery. In: Proceedings XIII International Cyclodextrin Symposium Torino Incontra Congress Centre, Torino, Italy, May 14-17, 2006:14–17.
28. Ahmed RZ, Patil G, Zaheer Z . Nanosponges—a completely new nano-horizon: pharmaceutical applications and recent advances. Drug Dev Ind Pharm 2012, 39:1263–1272.
29. Chilajwar SV, Pednekar PP, Jadhav KR, Gupta GJC, Kadam VJ . Cyclodextrin-based nanosponges: a propitious platform for enhancing drug delivery. Expert Opin Drug Deliv 2013, 11:111–120.
30. S S, S A, Krishnamoorthy K, Rajappan M . Nanosponges: a novel class of drug delivery system—review. J Pharm Pharm Sci 2012, 15:103–111.
31. Swaminathan S, Darandale S, Vavia PR . Drug delivery| bioavailability-nanosponge-aided drug delivery: a closer look. Pharm Formul Qual 2012, 14:12–15.
32. Tejashri G, Amrita B, Darshana J . Cyclodextrin based nanosponges for pharmaceutical use: a review. Acta Pharm 2013, 63, 335–358.
33. Trotta F, Cavalli R . Characterization and applications of new hyper-cross-linked cyclodextrins. Compos Interfaces 2009, 16:39–48.
34. Trotta F, Dianzani C, Caldera F, Mognetti B, Cavalli R . The application of nanosponges to cancer drug delivery. Expert Opin Drug Deliv 2014, 11:931–941.
35. Swaminathan S . Studies on novel dosage forms. Masters of pharmaceutical Sciences Dissertation submitted to the University of Mumbai, Mumbai, India, 2006.
36. Swaminathan S . Design and characterization of novel polymeric drug delivery system. Doctoral dissertation submitted to The University of Mumbai, Mumbai, India, 2010.
37. http://www.nanopinion.eu/sites/default/files/therapeutics_april_2009.pdf (Accessed October 01, 2016).
38. Trotta F, Shende P, Blasizzo M . Method for preparing dextrin nanosponges. 2012.
39. Castiglione F, Crupi V, Majolino D, Mele A, Panzeri W, Rossi B, Trotta F, Venuti V . Vibrational dynamics and hydrogen bond properties of β-CD nanosponges: an FTIR-ATR, Raman and solid-state NMR spectroscopic study. J Incl Phenom Macrocycl Chem 2013, 75:247–254.
40. Trotta F, Cavalli R, Tumiatti W, Zerbinati O, Roggero C, Vallero R . Ultrasound-assisted synthesis of cyclodextrin-based nanosponges. 2006.
41. Swaminathan S, Vavia PR, Trotta F, Cavalli R, Serpe L, Zara GP . Novel functionalized β cyclodextrin nanosponge based stable formulation of camptothecin and in vitro cytotoxicity evaluation. In: A Poster Presented at the Fifth Asian Cyclodextrin Conference in Busan, Korea, Conference Center of Sangnam International House in Pusan National University, Busan, South Korea, From 13 to 16 May, 2009.
42. Trotta F . Cyclodextrin nanosponges and their applications. In: Bilensoy E, ed. Cyclodextrins in Pharmaceutics, Cosmetics and Biomedicine, Current and Future Industrial Applications. Hoboken, New Jersey: John Wiley & Sons; 2011, 323–342.
43. Rossi B, Caponi S, Castiglione F, Corezzi S, Fontana A, Giarola M, Mariotto G, Mele A, Petrillo C, Trotta F, et al. Networking properties of cyclodextrin-based cross-linked polymers probed by inelastic light-scattering experiments. J Phys Chem B 2012, 116:5323–5327.
44. Crupi V, Fontana A, Giarola M, Majolino D, Mariotto G, Mele A, Melone L, Punta C, Rossi B, Trotta F, et al. Connection between the vibrational dynamics and the cross-linking properties in cyclodextrins-based polymers. J Raman Spectrosc 2013, 44:1457–1462.
45. Rossi B, Venuti V, Paciaroni A, Mele A, Longeville S, Natali F, Crupi V, Majolino D, Trotta F . Thermal fluctuations in chemically cross-linked polymers of cyclodextrins. Soft Matter 2015, 11:2183–2192.
46. Castiglione F, Crupi V, Majolino D, Mele A, Rossi B, Trotta F, Venuti V . Effect of cross-linking properties on the vibrational dynamics of cyclodextrins-based polymers: an experimental–numerical study. J Phys Chem B 2012, 116:7952–7958.
47. Rossi B, Fontana A, Giarola M, Mariotto G, Mele A, Punta C, Melone L, Toraldo F, Trotta F . Glass-like dynamics of new cross-linked polymeric systems: behavior of the Boson peak. J Non Cryst Solids 2014, 401:73–77.
48. Crupi V, Fontana A, Giarola M, Longeville S, Majolino D, Mariotto G, Mele A, Paciaroni A, Rossi B, Trotta F, et al. Vibrational density of states and elastic properties of cross-linked polymers: combining inelastic light and neutron scattering. J Phys Chem B 2014, 118:624–633.
49. Crupi V, Majolino D, Mele A, Rossi B, Trotta F, Venuti V . Modelling the interplay between covalent and physical interactions in cyclodextrin-based hydrogel: effect of water confinement. Soft Matter 2013, 9:6457–6464.
50. Castiglione F, Crupi V, Majolino D, Mele A, Melone L, Panzeri W, Punta C, Rossi B, Trotta F, Venuti V . Gel–sol evolution of cyclodextrin-based nanosponges: role of the macrocycle size. J Incl Phenom Macrocycl Chem 2014, 80:77–83.
51. Shende P, Kulkarni YA, Gaud RS, Deshmukh K, Cavalli R, Trotta F, Caldera F . Acute and repeated dose toxicity studies of different β-cyclodextrin-based nanosponge formulations. J Pharm Sci 2015, 104:1856–1863.
52. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA . Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata1,2. J Am Chem Soc 1966, 88:3888–3890.
53. Hertzberg RP, Caranfa MJ, Hecht SM . On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 1989, 28:4629–4638.
54. Hsiang YH, Hertzberg R, Hecht S, Liu LF . Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985, 260:14873–14878.
55. Takimoto CH, Wright J, Arbuck SG . Clinical applications of the camptothecins. Biochim Biophys Acta 1998, 1400:107–119.
56. Dancey J, Eisenhauer EA . Current perspectives on camptothecins in cancer treatment. Br J Cancer 1996, 74:327–338.
57. Koo OM, Rubinstein I, Onyuksel H . Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Nanomedicine 2005, 1:77–84.
58. Fassberg J, Stella VJ . A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992, 81:676–684.
59. Chourpa I, Millot J-M, Sockalingum GD, Riou J-F, Manfait M . Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy. Biochim Biophys Acta 1998, 1379:353–366.
60. Burke TG, Mishra AK, Wani MC, Wall ME . Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 1993, 32:5352–5364.
61. Venditto VJ, Simanek EE . Cancer therapies utilizing the camptothecins: a review of in vivo literature. Mol Pharm 2010, 7:307–349.
62. Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C, Rubin J, Burch PA, Adjei AA, Alberts SA, et al. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res 2000, 6:2236–2244.
63. Burris HAI, Awada A, Kuhn JG, Eckardt JR, Cobb PW, Rlnaldi DA, Fields S, Smith L, Von Hoff DD . Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anticancer Drugs 1994, 5:394–402.
64. Brandi G, Biasco G, Mirarchi MG, Golfieri R, Di Paolo A, Borghi A, Fanello S, Derenzini E, Agostini V, Giampalma E, et al. A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. Dig Liver Dis 2011, 43:1015–1021.
65. Berrada M, Serreqi A, Dabbarh F, Owusu A, Gupta A, Lehnert S . A novel non-toxic camptothecin formulation for cancer chemotherapy. Biomaterials 2005, 26:2115–2120.
66. Z-R H, S-c H, Yang Y-l, J-y F . Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta Pharmacol Sin 2008, 29:1094–1102.
67. Davis ME . Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv Drug Deliv Rev 2009, 61:1189–1192.
68. Kunii R, Onishi H, Machida Y . Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin. Eur J Pharm Biopharm 2007, 67:9–17.
69. Cortesi R, Esposito E, Maietti A, Menegatti E, Nastruzzi C . Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion. Int J Pharm 1997, 159:95–103.
70. Shenderova A, Burke TG, Schwendeman SP . Stabilization of 10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere delivery vehicles. Pharm Res 1997, 14:1406–1414.
71. Hatefi A, Amsden B . Camptothecin delivery methods. Pharm Res 2002, 19:1389–1399.
72. Gaur S, Wang Y, Kretzner L, Chen L, Yen T, Wu X, Yuan Y-C, Davis M, Yen Y . Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer. Nanomedicine 2014, 10:1477–1486.
73. Wang Z, Li Q, Zhao X, Sun B, Zhu Q, Gao W, Hua C . Preparation, formula optimization and antitumor actions of mannitol coupling camptothecin nanoparticles. Int J Pharm 2014, 465:360–367.
74. Gaur S, Chen L, Yen T, Wang Y, Zhou B, Davis M, Yen Y . Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer. Nanomedicine 2012, 8:721–730.
75. Gokduman K, Demir AS . Camptothecin anticancer drug loaded iron oxide micro and nanoparticles: tuning targeted and sustained release of the drug in bioactive form. Curr Nanosci 2013, 9:704–710.
76. Amna T, Hassan MS, Nam K-T, Bing YY, Barakat NAM, Khil M-S, Kim HY . Preparation, characterization, and cytotoxicity of CPT/Fe(2)O(3)-embedded PLGA ultrafine composite fibers: a synergistic approach to develop promising anticancer material. Int J Nanomedicine 2012, 7:1659–1670.
77. Minelli R, Cavalli R, Ellis L, Pettazzoni P, Trotta F, Ciamporcero E, Barrera G, Fantozzi R, Dianzani C, Pili R . Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. Eur J Pharm Sci 2012, 47:686–694.
78. Beevers CS, Huang S . Pharmacological and clinical properties of curcumin. Botanics 2011, 1:5–18.
79. Naksuriya O, Okonogi S, Schiffelers RM, Hennink WE . Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials 2014, 35:3365–3383.
80. Prasad S, Tyagi AK, Aggarwal BB . Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice. Cancer Res Treat 2014, 46:2–18.
81. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB . Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4:807–818.
82. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB . Curcumin and cancer: an ‘old-age’ disease with an ‘age-old’ solution. Cancer Lett 2008, 267:133–164.
83. Wang Y-J, Pan M-H, Cheng A-L, Lin L-I, Ho Y-S, Hsieh C-Y, Lin J-K . Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 1997, 15:1867–1876.
84. Tønnesen HH, Másson M, Loftsson T . Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm 2002, 244:127–135.
85. Kurien BT, Singh A, Matsumoto H, Scofield RH . Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Technol 2007, 5:567–576.
86. Sharma R, Steward W, Gescher A . Pharmacokinetics and pharmacodynamics of curcumin. In: Aggarwal B, Surh Y-J, Shishodia S, eds. The Molecular Targets and Therapeutic Uses of Curcumin in Health and Disease, vol. 595. New York: Springer; 2007, 453–470.
87. Surapaneni MS, Das SK, Das NG . Designing paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges. ISRN Pharmacol 2012, 2012:623139.
88. Bilensoy E, Gürkaynak O, Ertan M, Şen M, Hıncal AA . Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel. J Pharm Sci 2008, 97:1519–1529.
89. Esfandyari-Manesh M, Mostafavi SH, Majidi RF, Koopaei MN, Ravari NS, Amini M, Darvishi B, Ostad SN, Atyabi F, Dinarvand R . Improved anticancer delivery of paclitaxel by albumin surface modification of PLGA nanoparticles. DARU 2015, 23:28.
90. Agüeros M, Ruiz-Gatón L, Vauthier C, Bouchemal K, Espuelas S, Ponchel G, Irache JM . Combined hydroxypropyl-β-cyclodextrin and poly(anhydride) nanoparticles improve the oral permeability of paclitaxel. Eur J Pharm Sci 2009, 38:405–413.
91. He H, Chen S, Zhou J, Dou Y, Song L, Che L, Zhou X, Chen X, Jia Y, Zhang J, et al. Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel. Biomaterials 2013, 34:5344–5358.
92. Baek J-S, Cho C-W . 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells. J Pharm Pharmacol 2013, 65:72–78.
93. Ansari KA, Torne SJ, Vavia PR, Trotta F, Cavalli R . Paclitaxel loaded nanosponges: in vitro characterization and cytotoxicity study on MCF-7 cell line culture. Curr Drug Deliv 2011, 8:194–202.
94. Mognetti B, Barberis A, Marino S, Berta G, De Francia S, Trotta F, Cavalli R . In vitro enhancement of anticancer activity of paclitaxel by a Cremophor free cyclodextrin-based nanosponge formulation. J Incl Phenom Macrocycl Chem 2012, 74:201–210.
95. Jordan VC . Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 2006, 147:S269–S276.
96. Barbieri S, Sonvico F, Como C, Colombo G, Zani F, Buttini F, Bettini R, Rossi A, Colombo P . Lecithin/chitosan controlled release nanopreparations of tamoxifen citrate: loading, enzyme-trigger release and cell uptake. J Control Release 2013, 167:276–283.
97. Martínez A, Benito-Miguel M, Iglesias I, Teijón JM, Blanco MD . Tamoxifen-loaded thiolated alginate-albumin nanoparticles as antitumoral drug delivery systems. J Biomed Mater Res A 2012, 100:1467–1476.
98. Bhatia A, Singh B, Raza K, Shukla A, Amarji B, Katare OP . Tamoxifen-loaded novel liposomal formulations: evaluation of anticancer activity on DMBA-TPA induced mouse skin carcinogenesis. J Drug Target 2012, 20:544–550.
99. Bilensoy E . Amphiphilic cyclodextrin nanoparticles for effective and safe delivery of anticancer drugs. Adv Exp Med Biol 2015, 822:201.
100. Sarwa KK, Suresh PK, Debnath M, Ahmad MZ . Tamoxifen citrate loaded ethosomes for transdermal drug delivery system: preparation and characterization. Curr Drug Deliv 2013, 10:466–476.
101. Jain AS, Goel PN, Shah SM, Dhawan VV, Nikam Y, Gude RP, Nagarsenker MS . Tamoxifen guided liposomes for targeting encapsulated anticancer agent to estrogen receptor positive breast cancer cells: in vitro and in vivo evaluation. Biomed Pharmacother 2014, 68:429–438.
102. Pandey SK, Ghosh S, Maiti P, Haldar C . Therapeutic efficacy and toxicity of tamoxifen loaded PLA nanoparticles for breast cancer. Int J Biol Macromol 2015, 72:309–319.
103. Vivek R, Nipun Babu V, Thangam R, Subramanian KS, Kannan S . pH-responsive drug delivery of chitosan nanoparticles as tamoxifen carriers for effective anti-tumor activity in breast cancer cells. Colloids Surf B Biointerfaces 2013, 111:117–123.
104. How CW, Rasedee A, Manickam S, Rosli R . Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: characterization, stability assessment and cytotoxicity. Colloids Surf B Biointerfaces 2013, 112:393–399.
105. Amri A, Chaumeil JC, Sfar S, Charrueau C . Review: administration of resveratrol: what formulation solutions to bioavailability limitations? J Control Release 2012, 158:182–193.
106. Vian MA, Tomao V, Gallet S, Coulomb PO, Lacombe JM . Simple and rapid method for cis- and trans-resveratrol and piceid isomers determination in wine by high-performance liquid chromatography using chromolith columns. J Chromatogr A 2005, 1085:224–229.
107. Baur JA, Sinclair DA . Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006, 5:493–506.
108. Wenzel E, Somoza V . Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 2005, 49:472–481.
109. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK . High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004, 32:1377–1382.
110. Cottart C-H, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux J-L . Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 2010, 54:7–16.
111. Lu Z, Cheng B, Hu Y, Zhang Y, Zou G . Complexation of resveratrol with cyclodextrins: solubility and antioxidant activity. Food Chem 2009, 113:17–20.
112. Amri A, Le Clanche S, Thérond P, Bonnefont-Rousselot D, Borderie D, Lai-Kuen R, Chaumeil J-C, Sfar S, Charrueau C . Research paper: resveratrol self-emulsifying system increases the uptake by endothelial cells and improves protection against oxidative stress-mediated death. Eur J Pharm Biopharm 2014, 86:418–426.
113. Friedrich RB, Kann B, Coradini K, Offerhaus HL, Beck RCR, Windbergs M . Skin penetration behavior of lipid-core nanocapsules for simultaneous delivery of resveratrol and curcumin. Eur J Pharm Sci 2015, 78:204–213.
114. Teskač K, Kristl J . The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm 2010, 390:61–69.
115. Caddeo C, Manconi M, Fadda AM, Lai F, Lampis S, Diez-Sales O, Sinico C . Nanocarriers for antioxidant resveratrol: formulation approach, vesicle self-assembly and stability evaluation. Colloids Surf B Biointerfaces 2013, 111:327–332.
116. Chauhan AS . Dendrimer nanotechnology for enhanced formulation and controlled delivery of resveratrol. Ann N Y Acad Sci 2015, 1348:134–140.
117. Pando D, Matos M, Gutiérrez G, Pazos C . Formulation of resveratrol entrapped niosomes for topical use. Colloids Surf B Biointerfaces 2015, 128:398–404.
118. Jagtap S, Meganathan K, Wagh V, Winkler J, Hescheler J, Sachinidis A . Chemoprotective mechanism of the natural compounds, epigallocatechin- 3-o-gallate, quercetin and curcumin against cancer and cardiovascular diseases. Curr Med Chem 2009, 16:1451–1462.
119. Wang Q, Bao Y, Ahire J, Chao Y . Co-encapsulation of biodegradable nanoparticles with silicon quantum dots and quercetin for monitored delivery. Adv Healthc Mater 2013, 2:459–466.
120. Kumari A, Yadav SK, Pakade YB, Singh B, Yadav SC . Development of biodegradable nanoparticles for delivery of quercetin. Colloids Surf B Biointerfaces 2010, 80:184–192.
121. Tran TH, Guo Y, Song D, Bruno RS, Lu X . Quercetin-containing self-nanoemulsifying drug delivery system for improving oral bioavailability. J Pharm Sci 2014, 103:840–852.
122. Gao L, Liu G, Wang X, Liu F, Xu Y, Ma J . Preparation of a chemically stable quercetin formulation using nanosuspension technology. Int J Pharm 2011, 404:231–237.
123. Sambandam B, Ayyaswamy A, Thiyagarajan D, Kumar SS, Yadav BN . Synthesis and characterization of poly D-L lactide (PLA) nanoparticles for the delivery of quercetin. Int J Pharm Pharm Sci 2015, 7:42–49.
124. Aditya NP, Macedo AS, Doktorovova S, Souto EB, Kim S, Chang P-S, Ko S . Development and evaluation of lipid nanocarriers for quercetin delivery: a comparative study of solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and lipid nanoemulsions (LNE). LWT—Food Sci Technol 2014, 59:115–121.
125. Lai F, Franceschini I, Corrias F, Sala MC, Cilurzo F, Sinico C, Pini E . Maltodextrin fast dissolving films for quercetin nanocrystal delivery. A feasibility study. Carbohydr Polym 2015, 121:217–223.
126. Hazra M, Dasgupta Mandal D, Mandal T, Bhuniya S, Ghosh M . Designing polymeric microparticulate drug delivery system for hydrophobic drug quercetin. Saudi Pharm J 2015, 23:429–436.
127. Dinesh Kumar V, Verma PRP, Singh SK . Development and evaluation of biodegradable polymeric nanoparticles for the effective delivery of quercetin using a quality by design approach. LWT—Food Sci Technol 2015, 61:330–338.
128. Jeon S, Yoo CY, Park SN . Improved stability and skin permeability of sodium hyaluronate-chitosan multilayered liposomes by Layer-by-Layer electrostatic deposition for quercetin delivery. Colloids Surf B Biointerfaces 2015, 129:7–14.
129. Bagad M, Khan ZA . Poly(n-butylcyanoacrylate) nanoparticles for oral delivery of quercetin: preparation, characterization, and pharmacokinetics and biodistribution studies in Wistar rats. Int J Nanomedicine 2015, 10:3921–3935.
130. Han SB, Kwon SS, Jeong YM, Yu ER, Park SN . Physical characterization and in vitro skin permeation of solid lipid nanoparticles for transdermal delivery of quercetin. Int J Cosmet Sci 2014, 36:588–597.
131. Vaupel P, Mayer A . Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26:225–239.
132. Jain DS, Athawale RB, Bajaj AN, Shrikhande SS, Goel PN, Nikam Y, Gude RP . Unraveling the cytotoxic potential of temozolomide loaded into PLGA nanoparticles. DARU 2014, 22:18.
133. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C . Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 1997, 23:35–61.
134. Chen Z, Lai X, Song S, Zhu X, Zhu J . Nanostructured lipid carriers based temozolomide and gene co-encapsulated nanomedicine for gliomatosis cerebri combination therapy. Drug Deliv 2015:1–5. (Epub ahead of print).
135. Dilnawaz F, Sahoo SK . Research paper: enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model. Eur J Pharm Biopharm 2013, 85:452–462.
136. Di Martino A, Sedlarik V . Pharmaceutical nanotechnology: amphiphilic chitosan-grafted-functionalized polylactic acid based nanoparticles as a delivery system for doxorubicin and temozolomide co-therapy. Int J Pharm 2014, 474:134–145.
137. Dou M, Huang G, Xi Y, Zhang N . Orthogonal experiments for optimizing the formulation and preparation conditions of temozolomide solid lipid nanoparticles. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2008, 25:1141–1145.
138. Jain A, Jain SK . Formulation and optimization of temozolomide nanoparticles by 3 factor 2 level factorial design. Biomatter 2013, 3:e25102-1 to e25102-13.
139. Thirupathy A, Srinivas P, Ravindhra Babu DS, Mamidi S . Formulation and evaluation of sustained release implantable microspheres of temozolomide for brain targeting prepared by a novel technique. Int J Pharm Pharm Sci 2011, 3:187–194.
140. Cavalli R, Trotta F, Tumiatti W, Serpe L, Zara GP . 5-Fluorouracil loaded β-cyclodextrin nanosponges: in vitro characterization and cytotoxicity. In: Proceedings XIII International Cyclodextrin Symposium, Turin, Italy, 14–17 May, 2006: 207
141. Rivankar S . An overview of doxorubicin formulations in cancer therapy. J Cancer Res Ther 2014, 10:853–858.
142. Bhaskar C, Ahmed F, Kondapi AK, Golla K . A target-specific oral formulation of doxorubicin-protein nanoparticles: efficacy and safety in hepato-cellular cancer. J Cancer Educ 2013, 4:644–652.
143. Mura P, Bragagni M, Mennini N, Ghelardini C . Development and characterization of niosomal formulations of doxorubicin aimed at brain targeting. J Pharm Pharm Sci 2012, 15:184–196.
144. Candido CD, Campos ML, Correa Vidigal Assumpção JU, Pestana KC, Padilha EC, Carlos IZ, Peccinini RG . Biocompatible microemulsion modifies the tissue distribution of doxorubicin. J Pharm Sci 2014, 103:3297–3301.
145. Elbialy NS, Fathy MM, Khalil WM . Technical notes: preparation and characterization of magnetic gold nanoparticles to be used as doxorubicin nanocarriers. Phys Med 2014, 30:843–848.
146. Jiang SP, Lu XY, Li YL, Feng DL, Du YZ, Hu FQ, Yuan H, He SN, Yu HY . Preparation and characteristics of lipid nanoemulsion formulations loaded with doxorubicin. Int J Nanomedicine 2013, 8:3141–3150.
147. Ryan GM, Kaminskas LM, Bulitta JB, McIntosh MP, Owen DJ, Porter CJH . PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. J Control Release 2013, 172:128–136.
148. Win KY, Teng CP, Ye E, Low M, Han MY . Evaluation of polymeric nanoparticle formulations by effective imaging and quantitation of cellular uptake for controlled delivery of doxorubicin. Small 2015, 11:1197–1204.
149. Levacheva I, Tazina E, Levachev S, Baryshnikova M, Oborotova N, Baryshnikov A, Samsonova O, Beck-Broichsitter M, Strehlow B, Bakowsky U . Optimized thermosensitive liposomes for selective doxorubicin delivery: formulation development, quality analysis and bioactivity proof. Colloids Surf B Biointerfaces 2014, 121:248–256.
150. Mohamed SP, Pramod KT . Development and characterization of chitosan-polycarbophil interpolyelectrolyte complex-based 5-flurouracil formulations for buccal, vaginal and rectal application. DARU 2012, 20, 67:1–11.
151. Yassin AEB, Anwer MK, Mowafy HA, El-Bagory IM, Bayomi MA, Alsarra IA . Optimization of 5-flurouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer. Int J Med Sci 2010, 7:398–408.
152. Wilson B, Ambika TV, Dharmesh Kumar Patel R, Jenita JL, Priyadarshini SRB . Nanoparticles based on albumin: preparation, characterization and the use for 5-flurouracil delivery. Int J Biol Macromol 2012, 51:874–878.
153. Mallamma T, Thippeswamy BS, Bharathi DR, Snehalatha, Nagaraja TS, Yogananda R, Vyjayanthimala T, Mahanthesha MK . Formulation and evaluation of 5-flurouracil loaded HSA nanoparticle for controlled drug delivery. Int J Adv Res 2013, 7:23–30.
154. Nasr M, Saad IE . Formulation and evaluation of mastic gum as a compression coat for colonic delivery of 5-flurouracil. Int J Drug Deliv 2011, 3:481–491.
155. Sahoo SK, Sahoo SK, Behera A, Patil SV, Panda SK . Formulation, in vitro drug release study and anticancer activity of 5-Fluorouracil loaded gellan gum microbeads. Acta Pol Pharm 2013, 70:123–127.
156. Cavalli R, Argenziano M, Dianzani C . Disulfide nanosponges as innovative glutathione-responsive nanocarrier for doxorubicin delivery. In: 41st CRS Meeting, Chicago, IL, July 13–16, 2014.
157. Trotta F . New glutathione bio-responsive cyclodextrin nanosponges. In: 3rd European Cyclodextrin Congress, Antalya, Turkey, October 2–4, 2013.